NYSE:MRK 7 December 2025 - 20 December 2025

Merck & Co., Inc. finished Friday’s regular session modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline assets.

Merck & Co., Inc. stock traded higher on Friday, December 19, 2025, as investors balanced two big forces that tend to move large-cap pharma: U.S. drug-pricing policy headlines and pipeline-driven growth prospects. Shares were around $101.71, up about 1% from the prior close, as the market digested White House signals on new pricing agreements and fresh read-throughs from late-2025 clinical and regulatory developments.

December 18, 2025 — Merck & Company, Inc. is back in the spotlight for investors today as three threads converge: a fresh Wall Street upgrade tied to Merck’s post‑Keytruda strategy, a potentially meaningful FDA fast‑track development for two pipeline assets, and new Phase 3 momentum for the company’s blockbuster oncology franchise in earlier‑stage bladder cancer.

December 15, 2025 — Merck & Co., Inc. traded around $99.59 in Monday afternoon action, down about 0.23% on the day, as investors balanced a fresh wave of bullish analyst updates against a busy set of catalysts spanning Winrevair, Keytruda, vaccines, and headline regulatory scrutiny.

Merck & Co., Inc. ended Friday, December 12, 2025, at $100.30, climbing 1.30% on the day and finishing slightly higher for the week after a choppy stretch driven by vaccine-policy headlines and scrutiny around RSV preventive therapies. StockAnalysis

Merck & Co., Inc. closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the day, after trading between an intraday low of $96.06 and a high of $99.85. Volume was elevated at about 15.3 million shares, above recent averages, signaling active institutional and trader participation.StockAnalysis

Merck & Co., Inc. is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached in late November. That pullback comes after a powerful rebound from a May low near $76, driven by excitement over new cardiovascular and respiratory drugs, plus a $9.2 billion flu‑drug acquisition — even as investors remain focused on the looming 2028 patent cliff for Keytruda and fresh regulatory headwinds.Finviz+2Reuters+2

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a mix of powerful growth catalysts and fresh legal and financing questions that could shape the next leg of its move.